QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
NASDAQ:LPCN

Lipocine - LPCN Stock Forecast, Price & News

$0.46
+0.01 (+2.21%)
(As of 10/3/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.44
$0.46
50-Day Range
$0.39
$0.82
52-Week Range
$0.36
$1.89
Volume
63,860 shs
Average Volume
492,738 shs
Market Capitalization
$40.92 million
P/E Ratio
11.56
Dividend Yield
N/A
Price Target
N/A

Lipocine MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
2.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of Lipocine in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$41,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.14) to ($0.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

875th out of 1,093 stocks

Pharmaceutical Preparations Industry

433rd out of 548 stocks

LPCN stock logo

About Lipocine (NASDAQ:LPCN) Stock

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Stock News Headlines

LPCN: TLANDO Launched
Lipocine: Q2 Earnings Snapshot
Recap: Lipocine Q2 Earnings - Benzinga
Form 8-K Lipocine Inc. For: Aug 08 - StreetInsider.com
See More Headlines
Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Company Calendar

Last Earnings
8/08/2022
Today
10/03/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LPCN
Employees
13
Year Founded
N/A

Profitability

Net Income
$-630,000.00
Pretax Margin
20.57%

Debt

Sales & Book Value

Annual Sales
$16.14 million
Cash Flow
$0.05 per share
Book Value
$0.52 per share

Miscellaneous

Free Float
83,908,000
Market Cap
$40.92 million
Optionable
Optionable
Beta
0.60

Key Executives

  • Dr. Mahesh V. Patel Ph.D. (Age 65)
    Co-Founder, Interim Principal Financial Officer, Chairman, Pres & CEO
    Comp: $681.52k
  • Mr. Morgan R. Brown CPA (Age 54)
    CPA, M.B.A., MBA, Corp. Sec.
    Comp: $472.45k
  • Mr. Nachiappan Chidambaram Ph.D. (Age 53)
    VP of Product Devel.
    Comp: $323.22k
  • Mr. Logan Morse (Age 52)
    VP of Sales, Marketing & Operations
  • Ms. Krista Fogarty (Age 54)
    Principal Accounting Officer & Corp. Controller
  • Dr. Anthony DelConte M.D. (Age 64)
    M. D., Chief Medical Director













LPCN Stock - Frequently Asked Questions

How have LPCN shares performed in 2022?

Lipocine's stock was trading at $0.9911 at the start of the year. Since then, LPCN stock has decreased by 53.4% and is now trading at $0.4623.
View the best growth stocks for 2022 here
.

When is Lipocine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our LPCN earnings forecast
.

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) released its earnings results on Monday, August, 8th. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, meeting analysts' consensus estimates of ($0.04). The specialty pharmaceutical company earned $0.50 million during the quarter, compared to the consensus estimate of $0.30 million.

What other stocks do shareholders of Lipocine own?
What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

How do I buy shares of Lipocine?

Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lipocine's stock price today?

One share of LPCN stock can currently be purchased for approximately $0.46.

How much money does Lipocine make?

Lipocine (NASDAQ:LPCN) has a market capitalization of $40.92 million and generates $16.14 million in revenue each year. The specialty pharmaceutical company earns $-630,000.00 in net income (profit) each year or $0.04 on an earnings per share basis.

How can I contact Lipocine?

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The official website for the company is www.lipocine.com. The specialty pharmaceutical company can be reached via phone at (801) 994-7383, via email at john.woolford@westwicke.co, or via fax at 801-994-7388.

This page (NASDAQ:LPCN) was last updated on 10/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.